Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Gains License to DNAPrint s SNPs

NEW YORK, Oct 24 – Orchid BioSciences has purchased an option to co-develop and co-commercialize DNAPrint genomics’ SNP-disease associations and other intellectual properties, the companies said Tuesday.

The option provides Orchid exclusive rights to negotiate partnership terms with DNAPrint for existing and future products and properties, including genetic algorithms, software, and information resources such as SNP and haplotype associations with complex human traits and diseases.

Other terms of the agreement were not disclosed.

DNAPrint is developing genetic analytics and information resources for personalized medicine. The company aims to provide practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.